Table 4 Hazard ratios (95% CI) for hemorrhagic stroke according to sleep duration.

From: Long Sleep Duration and Risk of Ischemic Stroke and Hemorrhagic Stroke: the Kailuan Prospective Study

 

Sleep duration

<6 h

6–8 h

>8 h

Cases (%)

55 (0.83)

560 (0.65)

16 (1.00)

 Model 1 †

1.07 (0.81–1.42)

reference

1.64 (0.99–2.69)

 Model 2 ‡

1.10 (0.83–1.45)

reference

1.70 (1.03–2.80)

 Model 3 §

0.95 (0.73–1.24)

reference

1.60 (0.97–2.63)

 Model 4 ※

1.06 (0.80–1.40)

reference

1.63 (0.99–2.69)

 Sensitivity analysis*

1.03 (0.77–1.37)

reference

1.67 (1.01–2.75)

women

 Cases (%)

7 (0.63)

68 (0.38)

4 (1.07)

Model 1 †

1.26 (0.57–2.79)

reference

4.49 (1.61–12.49)

Model 2 ‡

1.29 (0.58–2.88)

reference

4.61 (1.65–12.88)

Model3 §

1.01 (0.47–2.15)

reference

3.39 (1.21–9.50)

Model 4 ※

1.27 (0.57–2.85)

reference

3.58 (1.28–10.06)

Sensitivity analysis*

1.11 (0.47–2.63)

reference

3.60 (1.28–10.12)

men

 Cases (%)

48 (0.87)

492 (0.72)

12 (0.98)

Model 1 †

1.05 (0.78–1.41)

reference

1.36 (0.77–2.42)

Model 2 ‡

1.07 (0.79–1.45)

reference

1.42 (0.80–2.52)

Model 3 §

1.05 (0.79–1.40)

reference

1.62 (0.98–2.67)

Model 4 ※

1.04 (0.77–1.41)

reference

1.38 (0.77–2.45)

Sensitivity analysis*

1.03 (0.75–1.40)

reference

1.41 (0.79–2.50)

  1. CI, confidence interval.
  2. †Model 1 was stratified by hospitals, and adjusted for age and sex.
  3. ‡Model 2 was stratified by hospitals, and adjusted for as model 1 plus marital status, family per member monthly income, education level, smoking status, drinking status, physical activity, and family history of stroke.
  4. §Model 3 was stratified by hospitals, and adjusted for the variables in Model 2 plus body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, total cholesterol, hypotensive drug use, lipid-lowering drug use, hypoglycemic drug use, history of myocardial infarction, and snoring status.
  5. ※Model 4 was stratified by hospitals, and adjusted for the variables in Model 3 plus high sensitive C-reactive protein, and atrial fibrillation.
  6. *Adjusted for model 3 and further excluded individuals with myocardial infarction and cancer.
Back to article page